

*ELECTRONIC SUPPLEMENTARY INFORMATION FOR:*

## **Incorporation of chlorinated analogues of aliphatic amino acids during cell-free protein synthesis**

**Dannon J. Stigers,<sup>a</sup> Zachary I. Watts,<sup>a</sup> James E. Hennessy,<sup>a</sup> Hye-Kyung Kim,<sup>a</sup> Romeo Martini,<sup>a</sup> Matthew C. Taylor,<sup>b</sup> Kiyoshi Ozawa,<sup>c</sup> Jeffrey W. Keillor,<sup>a,d</sup> Nicholas E. Dixon,<sup>c</sup> and Christopher J. Easton<sup>\*a</sup>**

<sup>a</sup> ARC Centre of Excellence for Free Radical Chemistry and Biotechnology, Research School of Chemistry, Australian National University, Canberra ACT 0200, Australia; <sup>b</sup> CSIRO Entomology, Canberra ACT 2601, Australia; <sup>c</sup> School of Chemistry, University of Wollongong, Wollongong NSW 2522, Australia; <sup>d</sup> Current address: Département de Chimie, Université de Montréal, Montréal Québec H3C 3J7, Canada

**E-mail: easton@rsc.anu.edu.au**


<b>CONTENTS</b>	<b>Page</b>
1. General Experimental	S2
2. Synthetic Procedures	S3
3. Cell-Free Protein Synthesis	S4
4. Hydrolysis of Chlorides <b>1a,b</b> , <b>2a,b</b> and <b>3a,b</b>	S4
5. ESI Mass Spectrometry of Purified Proteins	S5
6. Activity Assay for PpiB	S8
7. IleRS Activity Assay	S12
8. References	S12

## 1. GENERAL EXPERIMENTAL

<sup>1</sup>H NMR spectra were recorded using a Varian 300 spectrometer. Deuterium oxide with an isotopic purity of 99.75% was purchased from Cambridge Isotope Laboratories Inc., MA, USA. HPLC was carried out using a Waters Alliance Separation Module 2695 with a Waters 2996 photodiode array detector. Ultrapure water (resistivity >15 MΩ cm<sup>-1</sup>) was prepared using a Milli-Q<sup>®</sup> reagent system. Plasmid DNA encoding for His<sub>6</sub>-PpiB with expression under control of the phage T7 promoter (pND1098) was as described.<sup>S1</sup> Plasmid DNA was prepared from *E. Coli* DH5α/pND1098 with the Qiagen<sup>®</sup> Plasmid Maxi kit. T7 RNA polymerase (50,000 U/mL) was obtained from New England BioLabs Inc., MA, USA. Spectra/Por<sup>®</sup> dialysis membrane (#2, MWCO: 12-14,000) was purchased from Spectrum Laboratories, Inc. USA. SDS-PAGE gels were run on a Mini-PROTEIN<sup>®</sup> Tetra system and stained with Bio-Safe<sup>®</sup> Coomassie Blue stain from Bio-Rad, CA, USA. Acrylamide, bis-acrylamide and SDS-PAGE molecular weight standards (low range) solutions were purchased from Bio-Rad, CA, USA. Proteins were purified with a His GraviTrap<sup>®</sup> Kit from GE Healthcare and concentrated with Amicon<sup>®</sup> Ultra-4 (YM-10) centrifugal devices from Millipore, MA, USA. Protein mass spectral data were acquired by direct injection onto an Agilent 1100 series LC/MSD TOF instrument operating in the positive ESI ionisation mode. PpiB substrate (*N*-succinyl-(*S*)-Ala-(*S*)-Ala-(*S*)-Pro-(*S*)-Phe-4-nitroanilide) was purchased from Sigma Chemical Co. Ultraviolet (UV) spectra were recorded using a Shimadzu UV-2450 UV-Vis scanning spectrophotometer.

## 2. SYNTHETIC PROCEDURES

**Scheme S1.** Preparation of the amino acids **1a** and **1b**.



i) Cbz-Cl, NaHCO<sub>3</sub>, H<sub>2</sub>O; ii) HBTU, CH<sub>2</sub>Cl<sub>2</sub>; iii) LiCl, THF; iv) H<sub>2</sub>, Pd/C, EtOH.

The individual diastereomers **1a** and **1b** were prepared using the previously reported<sup>S2</sup> sequence shown in Scheme S1. Their purification was carried out through HPLC (Phenomenex Luna C18 column, 250 mm × 4.6 mm, 5 μm, 1 mL/min, 12 mM HCl mobile phase). Their <sup>1</sup>H NMR spectra are consistent with published data.<sup>S2</sup>

### 3. CELL-FREE PROTEIN SYNTHESIS

Cell-free protein synthesis was carried out following our published procedure<sup>S3</sup> with the following few modifications. (*S*)-Ala and RNasin were not added to the inner mixture. Commercially obtained T7 RNA polymerase (2  $\mu$ L) was added to the inner mixture of each reaction instead of the plasmid encoding for this enzyme. A 5  $\mu$ L quantity of total tRNA solution was added instead of 10  $\mu$ L. The His<sub>6</sub>-PpiB sequence (with an additional C-terminal Asn residue,<sup>S1</sup> mass = 19221 Da, *N*-formyl-His<sub>6</sub>-PpiB = 19250 Da) is

MHHHHHMMVT FHTNHGDIVI KTFDDKAPET VKNFLDYCRE GFYNNTIFHR VINGFMIQGG  
GFEPGMKQKA TKEPIKNEAN NGLKNTRGTL AMARTQAPHS ATAQFFINVV DNDFLNFSGE  
SLQGWGYCVF AEVVDGMDVV DKIKGVATGR SGMHQDVPKE DVIIESVTVS EN.


The protein yields from the experiments represented by the lanes on the SDS-PAGE illustrated in Fig. 1 of the manuscript were as follows: b) 100  $\mu$ g; c) 13  $\mu$ g; d) 110  $\mu$ g; e) 39  $\mu$ g; f) 150  $\mu$ g; g) 48  $\mu$ g; and h) 40  $\mu$ g.

### 4. HYDROLYSIS OF THE CHLORIDES **1a,b**, **2a,b** AND **3a,b**


A mixture of the chlorides **2a,b** (54 mg, 0.2 mmol) dissolved in D<sub>2</sub>O (2 mL) adjusted to pH 7 through the addition of a solution of NaOD in D<sub>2</sub>O (2.5 M), was placed in an NMR tube at a constant temperature of 37 °C for 6 h. <sup>1</sup>H NMR spectra were recorded periodically. Integration of the spectra, relative to an internal standard, was used to determine the half-lives. Under the same conditions, no reaction of the chlorides **1a,b** or **3a,b** was evident.

## 5. ESI MASS SPECTROMETRY OF PURIFIED PROTEINS


Protein solution (50  $\mu\text{L}$ ) was diluted with a 50:50 (v/v) solution of 0.1% formic acid in MeCN:0.1% aqueous formic acid (150  $\mu\text{L}$ ) followed by direct injection into the spectrometer. Mass spectra of PpiB synthesised in the presence of the chlorides **2a,b** (2 mM) instead of (*S*)-Leu (**5**) (1 mM), and native protein are shown in Figure S1. Mass spectra of protein produced with the chloride **1a** (0.2 or 0.02 mM) instead of (*S*)-Val (**4**) (1 mM), and native protein are shown in Figure S2. Mass spectra of protein produced with the chloride **1b** (0.2 or 0.02 mM) instead of (*S*)-Val (**4**) (1 mM) and native protein are shown in Figure S3.



**Figure S1.** Mass spectra of a) native PpiB and b) PpiB produced using the chlorides **2a,b** (2 mM) instead of (*S*)-Leu (**5**) (1 mM).



**Figure S2.** Mass spectra of: a) native PpiB; b) PpiB produced using the chloride **1a** (0.02 mM) instead of (*S*)-Val (**4**) (1 mM); and c) PpiB produced using the chloride **1a** (0.2 mM) instead of (*S*)-Val (**4**) (1 mM).




**Figure S3.** Mass spectra of: a) native PpiB; b) PpiB produced using the chloride **1b** (0.02 mM) instead of (S)-Val (**4**) (1 mM); and c) PpiB produced using the chloride **1b** (0.2 mM) instead of (S)-Val (**4**) (1 mM).


## 6. ACTIVITY ASSAY FOR PpiB

Enzyme activity was determined under similar conditions to those reported.<sup>S4</sup> Peptide substrate (*N*-succinyl-(*S*)-Ala-(*S*)-Ala-(*S*)-Pro-(*S*)-Phe-4-nitroanilide, 25 mg, 0.04 mmol) was dissolved in a solution of LiCl in trifluoroethanol (0.3 M, 66 mL, 0.6 mM). The assay buffer (800  $\mu$ L, 50 mM HEPES, 100 mM NaCl, pH 8.0) was added to a quartz cuvette and cooled to 0 °C, before the UV-Vis trace was recorded as a baseline. The peptide solution (25  $\mu$ L) was then added and the UV-Vis absorbance was recorded followed by the addition of a chymotrypsin (CHT) solution (5  $\mu$ L, 1 mg/mL in 1 mM HCl). PpiB solution (5  $\mu$ L, 49  $\mu$ M, 20 mM phosphate, 0.5 M NaCl, pH 7.4) was added and the absorbance at 390 nm was followed until the reaction was complete. The UV-Vis traces without the addition of PpiB are shown in Figure S4. The UV-Vis traces for native enzyme are shown in Figure S5 and those for PpiB produced with the chloride **1a** (2 mM) instead of (*S*)-Val (**4**) (1 mM) are shown in Figure S6. A comparison of the absorbances at 390 nm over time of all three experiments is shown in Figure S7.


The kinetic constants for native and chlorinated PpiB were also determined as previously reported<sup>S4</sup> by using twenty times the above concentration of PpiB and one thousand times the above concentration of chymotrypsin with various substrate concentrations ranging from 7.5 – 4,000  $\mu$ M. Under these conditions native PpiB had  $K_M$  and  $k_{cat}$  values of  $380 \pm 25 \mu\text{M}$  and  $1940 \pm 60 \text{ s}^{-1}$ , respectively, while the corresponding values for the chlorinated PpiB were  $590 \pm 50 \mu\text{M}$  and  $1110 \pm 50 \text{ s}^{-1}$ .




**Figure S4.** UV traces of the enzymatic cleavage of peptide substrate by CHT (6 µg/mL) without PpiB, at pH 8 over 26 min.



**Figure S5.** UV traces of the enzymatic cleavage of peptide substrate by CHT (6 µg/mL) in the presence of native PpiB (290 nM), at pH 8 over 26 min.



**Figure S6.** UV traces of the enzymatic cleavage of peptide substrate by CHT (6  $\mu\text{g/mL}$ ) in the presence of PpiB (290 nM) prepared from the chloride **1a** (2 mM) instead of (*S*)-Val (**4**) (1 mM), at pH 8 over 26 min.



**Figure S7.** Enzymatic activity of native PpiB and PpiB prepared from the chloride **1a** (2 mM) instead of (*S*)-Val (**4**) (1 mM) compared with substrate cleavage without PpiB.

## 7. IleRS ACTIVITY ASSAY

A mixture of an aqueous solution of (2*S*,3*S*)-Ile (**6**) (6  $\mu$ L, 10 mM) and one of ATP (5  $\mu$ L, 6 mM) in buffer (16.2  $\mu$ L, 40 mM Tris-HCl, 0.8 mM MgCl<sub>2</sub>, 3.2 mM KCl, pH 7.6) was incubated at 37 °C for 3 min before an aqueous IleRS solution (2.8  $\mu$ L, 16  $\mu$ M) was added. Aliquots (10  $\mu$ L) were removed immediately and after 16 h, and the enzyme activity quenched through the addition of aqueous sodium dodecylsulfate (10  $\mu$ L, 0.02% w/v). HPLC using an Alltech Alltima HP C18 column, eluting with a gradient of ammonium dihydrogen phosphate (60 mM) and tetrabutylammonium dihydrogen phosphate (5 mM) in water (solvent A) and tetrabutylammonium phosphate (5 mM) in methanol (solvent B), relative to standards, showed AMP production in the assay mixture to a concentration of 100  $\mu$ M. The analogous experiment carried out using a 1:1 mixture of the chlorides **3a,b** (6  $\mu$ L, 10 mM) instead of (2*S*,3*S*)-Ile (**6**) showed AMP production to a concentration of 210  $\mu$ M.

## 8. REFERENCES

- S1. K. Ozawa, M. J. Headlam, D. Mouradov, S. J. Watt, J. L. Beck, K. J. Rodgers, R. T. Dean, T. Huber, G. Otting and N. E. Dixon, *FEBS J.*, 2005, **272**, 3162–3171.
- S2. N. Valls, M. Borregán and J. Bonjoch, *Tetrahedron Lett.*, 2006, **47**, 3701–3705.
- S3. M. A. Apponyi, K. Ozawa, N. E. Dixon and G. Otting, in *Structural Proteomics: High Throughput Methods*, ed. B. Kobe, M. Guss and T. Huber, *Methods in Molecular Biology*, Humana Press, Totowa, NJ, 2008, vol. **426**, pp. 257–268.
- S4. J. L. Kofron, P. Kuzmič, V. Kishore, E. Colón-Bonilla and D. H. Rich, *Biochemistry*, 1991, **30**, 6127–6134.